[go: up one dir, main page]

SV2011003857A - Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. - Google Patents

Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.

Info

Publication number
SV2011003857A
SV2011003857A SV2011003857A SV2011003857A SV2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A SV 2011003857 A SV2011003857 A SV 2011003857A
Authority
SV
El Salvador
Prior art keywords
bifenil
carboxamida
dimetil
morfolin
metoxi
Prior art date
Application number
SV2011003857A
Other languages
English (en)
Inventor
Joginder Singh Bajwa
La Cruz Marilyn De
Stephanie Kay Dodd
Liladhar Murlindar Waykole
Raeann Wu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011003857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SV2011003857A publication Critical patent/SV2011003857A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PREPARAN Y SE CARACTERIZAN SALES DE N-[6-(CIS-2,6-DIMETIL-MORFOLIN-4-IL)-PIRIDIN-3-IL]-2-METIL-4'-(TRIFLUORO-METOXI)-[1,1'-BIFENIL]-3-CARBOXAMIDA
SV2011003857A 2008-09-17 2011-03-17 Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. SV2011003857A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9758008P 2008-09-17 2008-09-17

Publications (1)

Publication Number Publication Date
SV2011003857A true SV2011003857A (es) 2011-05-16

Family

ID=41228716

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003857A SV2011003857A (es) 2008-09-17 2011-03-17 Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.

Country Status (39)

Country Link
US (3) US8063043B2 (es)
EP (1) EP2342198B1 (es)
JP (2) JP4897938B2 (es)
KR (2) KR101129088B1 (es)
CN (1) CN102159570B (es)
AR (2) AR073591A1 (es)
AU (1) AU2009293444B2 (es)
BR (2) BRPI0918629B8 (es)
CA (1) CA2736751C (es)
CL (1) CL2011000551A1 (es)
CO (1) CO6351744A2 (es)
CR (1) CR20110126A (es)
CU (1) CU23860B1 (es)
DK (1) DK2342198T3 (es)
DO (1) DOP2011000082A (es)
EA (1) EA020048B1 (es)
EC (1) ECSP11010985A (es)
ES (1) ES2418485T3 (es)
GE (1) GEP20125592B (es)
HN (1) HN2011000745A (es)
HR (1) HRP20130597T1 (es)
IL (1) IL211412A (es)
JO (1) JO2889B1 (es)
MA (1) MA32717B1 (es)
MX (1) MX2011002805A (es)
MY (1) MY151100A (es)
NI (1) NI201100051A (es)
NZ (1) NZ591420A (es)
PE (1) PE20110292A1 (es)
PH (1) PH12012500399A1 (es)
PL (1) PL2342198T3 (es)
PT (1) PT2342198E (es)
SI (1) SI2342198T1 (es)
SM (1) SMT201300072B (es)
SV (1) SV2011003857A (es)
TW (1) TWI367883B (es)
UA (1) UA103049C2 (es)
WO (1) WO2010033481A1 (es)
ZA (1) ZA201101579B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
WO2014128661A1 (en) 2013-02-25 2014-08-28 Novartis Ag Oral formulation and suspension of an oncology drug
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
CN105906616B (zh) * 2015-03-30 2018-09-04 苏州晶云药物科技有限公司 Lde225单磷酸盐的晶型及其制备方法
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CA3017411C (en) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415022A (pt) * 2003-10-02 2006-11-28 Pharmacia & Upjohn Co Llc sais e polimorfos de um composto de indolinona substituìda com pirrol
GB0412468D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Also Published As

Publication number Publication date
SI2342198T1 (sl) 2013-07-31
HRP20130597T1 (en) 2013-07-31
CU23860B1 (es) 2013-02-26
PE20110292A1 (es) 2011-05-17
BR122020009045A2 (pt) 2020-11-10
UA103049C2 (uk) 2013-09-10
MX2011002805A (es) 2011-04-11
CN102159570A (zh) 2011-08-17
BR122020009045B1 (pt) 2022-08-02
CU20110055A7 (es) 2011-12-28
MA32717B1 (fr) 2011-10-02
TW201016686A (en) 2010-05-01
CA2736751A1 (en) 2010-03-25
AR073591A1 (es) 2010-11-17
CA2736751C (en) 2012-10-23
ZA201101579B (en) 2011-11-30
EP2342198A1 (en) 2011-07-13
JP2012097104A (ja) 2012-05-24
IL211412A0 (en) 2011-05-31
ECSP11010985A (es) 2011-05-31
SMT201300072B (it) 2013-09-06
BRPI0918629A2 (pt) 2020-10-27
KR101129088B1 (ko) 2012-03-23
JO2889B1 (en) 2015-03-15
NI201100051A (es) 2011-09-08
US20120214810A1 (en) 2012-08-23
HN2011000745A (es) 2014-01-06
DOP2011000082A (es) 2011-04-15
ES2418485T3 (es) 2013-08-14
AR113778A2 (es) 2020-06-10
DK2342198T3 (da) 2013-07-01
IL211412A (en) 2014-07-31
PH12012500399A1 (en) 2014-04-28
EA201100501A1 (ru) 2011-10-31
BRPI0918629B1 (pt) 2021-04-13
US8063043B2 (en) 2011-11-22
JP2012502912A (ja) 2012-02-02
US20110178085A1 (en) 2011-07-21
CO6351744A2 (es) 2011-12-20
CR20110126A (es) 2011-04-27
GEP20125592B (en) 2012-07-25
NZ591420A (en) 2012-07-27
US20120035174A1 (en) 2012-02-09
EA020048B1 (ru) 2014-08-29
KR20120015363A (ko) 2012-02-21
TWI367883B (en) 2012-07-11
PT2342198E (pt) 2013-07-10
EP2342198B1 (en) 2013-04-03
AU2009293444A1 (en) 2010-03-25
PL2342198T3 (pl) 2013-08-30
BRPI0918629B8 (pt) 2021-05-25
CL2011000551A1 (es) 2011-07-15
MY151100A (en) 2014-04-15
JP4897938B2 (ja) 2012-03-14
KR20110056325A (ko) 2011-05-26
HK1156628A1 (en) 2012-06-15
AU2009293444B2 (en) 2012-03-15
WO2010033481A1 (en) 2010-03-25
CN102159570B (zh) 2014-01-15

Similar Documents

Publication Publication Date Title
SV2011003857A (es) Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
EA201170227A1 (ru) Имидазолкарбоксамиды
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
UY30600A1 (es) Compuestos novedosos
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
PA8667201A1 (es) Nuevos compuestos farmaceuticos
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
TW201713640A (en) Bruton's tyrosine kinase inhibitors
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CR11861A (es) Compuestos organicos
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201290642A1 (ru) Соединения и способы
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
UY31688A1 (es) Plaguicidas
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA106880C2 (uk) Нові гербіциди
UY34191A (es) ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?.
UY33976A (es) Derivados de pirazolo-pirimidina.